Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2331) 2331
life sciences & biomedicine (2282) 2282
humans (2278) 2278
male (1476) 1476
female (1278) 1278
muscarinic antagonists - therapeutic use (1162) 1162
muscarinic antagonists - adverse effects (904) 904
middle aged (896) 896
aged (786) 786
muscarinic antagonists - administration & dosage (747) 747
treatment outcome (720) 720
adult (708) 708
pharmacology & pharmacy (691) 691
biological and medical sciences (682) 682
animals (672) 672
medical sciences (636) 636
urinary bladder, overactive - drug therapy (527) 527
urology & nephrology (442) 442
pulmonary disease, chronic obstructive - drug therapy (415) 415
muscarinic antagonists - pharmacology (401) 401
double-blind method (393) 393
urinary incontinence (383) 383
overactive bladder (378) 378
drug therapy (370) 370
respiratory system (351) 351
dose-response relationship, drug (316) 316
pharmacology. drug treatments (314) 314
administration, inhalation (304) 304
chronic obstructive pulmonary disease (296) 296
care and treatment (293) 293
quality of life (292) 292
aged, 80 and over (291) 291
time factors (285) 285
drug therapy, combination (280) 280
rats (276) 276
tolterodine tartrate (275) 275
neurosciences & neurology (269) 269
acetylcholine receptors (260) 260
analysis (260) 260
medicine & public health (257) 257
neurosciences (254) 254
lung diseases, obstructive (241) 241
general & internal medicine (233) 233
bronchodilator agents - administration & dosage (231) 231
adolescent (229) 229
pulmonary disease, chronic obstructive - physiopathology (220) 220
abridged index medicus (218) 218
research (215) 215
nephrology. urinary tract diseases (212) 212
muscarinic antagonists (206) 206
benzhydryl compounds - therapeutic use (205) 205
medicine, general & internal (202) 202
urinary incontinence - drug therapy (202) 202
urinary tract. prostate gland (200) 200
copd (197) 197
urinary system involvement in other diseases. miscellaneous (195) 195
severity of illness index (189) 189
bronchodilator agents - adverse effects (187) 187
young adult (186) 186
urology (181) 181
clinical trials (178) 178
dosage and administration (178) 178
benzhydryl compounds - adverse effects (175) 175
cresols - therapeutic use (171) 171
muscarinic antagonists - pharmacokinetics (165) 165
bronchodilator agents - therapeutic use (163) 163
adrenergic beta-2 receptor agonists - administration & dosage (161) 161
drug combinations (159) 159
psychiatry (158) 158
randomized controlled trials as topic (158) 158
pulmonary disease, chronic obstructive - diagnosis (157) 157
prospective studies (154) 154
pharmacology/toxicology (152) 152
solifenacin succinate (152) 152
mice (150) 150
internal medicine (148) 148
drug administration schedule (145) 145
cross-over studies (143) 143
receptors, muscarinic - drug effects (141) 141
cresols - adverse effects (140) 140
health aspects (140) 140
lung - drug effects (139) 139
drugs (138) 138
oxybutynin (138) 138
pharmacology (138) 138
bladder (136) 136
receptors, muscarinic - metabolism (135) 135
risk factors (133) 133
patients (131) 131
asthma (130) 130
phenylpropanolamine - therapeutic use (128) 128
toxicology (128) 128
tolterodine (127) 127
lung - physiopathology (126) 126
quinuclidines - therapeutic use (125) 125
diseases of the respiratory system (124) 124
mandelic acids - therapeutic use (124) 124
benzhydryl compounds - administration & dosage (122) 122
child (122) 122
delayed-action preparations (122) 122
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2950) 2950
German (41) 41
Spanish (22) 22
Russian (13) 13
Japanese (12) 12
French (9) 9
Chinese (4) 4
Portuguese (4) 4
Swedish (3) 3
Italian (2) 2
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
by Gray, Shelly L and Anderson, Melissa L and Dublin, Sascha and Hanlon, Joseph T and Hubbard, Rebecca and Walker, Rod and Yu, Onchee and Crane, Paul K and Larson, Eric B
JAMA internal medicine, ISSN 2168-6106, 01/2015, Volume 175, Issue 3, pp. 401 - 407
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Alzheimer Disease - etiology | Prospective Studies | Humans | Muscarinic Antagonists - adverse effects | Male | Dementia - epidemiology | Cholinergic Antagonists - administration & dosage | Histamine H1 Antagonists - adverse effects | Muscarinic Antagonists - administration & dosage | Dementia - chemically induced | Antidepressive Agents, Tricyclic - adverse effects | Histamine H1 Antagonists - administration & dosage | Aged, 80 and over | Alzheimer Disease - epidemiology | Female | Aged | Cholinergic Antagonists - adverse effects | Antidepressive Agents, Tricyclic - administration & dosage | Cohort Studies | Medical personnel | Care and treatment | Practice | Dosage and administration | Patients | Risk factors | Parasympatholytic agents | Dementia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
by Horita, Nobuyuki and Goto, Atsushi and Shibata, Yuji and Ota, Erika and Nakashima, Kentaro and Nagai, Kenjiro and Kaneko, Takeshi and Horita, Nobuyuki
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2018, Issue 2, pp. CD012066 - CD012066
Pneumonia | Lungs & airways | Adrenal Cortex Hormones | Pulmonary Disease, Chronic Obstructive | Administration, Inhalation | Muscarinic Antagonists | Beta‐agonists, long‐acting, once daily | Beta‐agonists, long‐acting, twice daily | Cause of Death | Disease Progression | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Steroids, inhaled | Adrenergic beta‐2 Receptor Agonists | Chronic obstructive pulmonary disease (stable) | Quality of Life | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Drug Therapy, Combination | Medicine General & Introductory Medical Sciences | Corticosteroids (inhaled, oral or intranasal) | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pneumonia - etiology | Humans | Muscarinic Antagonists - adverse effects | Muscarinic Antagonists - therapeutic use | Drug Therapy, Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
by Abrams, Paul and Kelleher, Con and Staskin, David and Rechberger, Tomasz and Kay, Richard and Martina, Reynaldo and Newgreen, Donald and Paireddy, Asha and van Maanen, Rob and Ridder, Arwin
European urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 577 - 588
Urology | Overactive bladder | Solifenacin | Combination therapy | Mirabegron | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Urodynamics - drug effects | Male | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Thiazoles - adverse effects | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Acetanilides - therapeutic use | Adult | Female | Acetanilides - adverse effects | Urological Agents - therapeutic use | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Europe | Treatment Outcome | Solifenacin Succinate - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Solifenacin Succinate - adverse effects | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Drug Combinations | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Potential Future Pharmacological Treatment of Bladder Dysfunction
by Andersson, Karl‐Erik
Basic & clinical pharmacology & toxicology, ISSN 1742-7835, 10/2016, Volume 119, Issue S3, pp. 75 - 85
Drugs, Investigational - adverse effects | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Drugs, Investigational - therapeutic use | Male | Acetylcholine Release Inhibitors - adverse effects | Muscarinic Antagonists - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Urinary Bladder - innervation | Cannabinoids - adverse effects | Purinergic P2X Receptor Antagonists - adverse effects | Urinary Bladder, Neurogenic - physiopathology | Urinary Bladder, Overactive - drug therapy | Urinary Bladder, Overactive - physiopathology | Female | Phosphodiesterase 5 Inhibitors - therapeutic use | Neurons, Efferent - metabolism | Purinergic P2X Receptor Antagonists - therapeutic use | Neurons, Afferent - drug effects | Neurons, Efferent - drug effects | Urinary Bladder, Neurogenic - drug therapy | Cannabinoids - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Animals | Acetylcholine Release Inhibitors - therapeutic use | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Neurons, Afferent - metabolism | Drug approval | Bladder | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Allergic Contact Dermatitis to Ophthalmic Medications: Relevant Allergens and Alternative Testing Methods
by Grey, Katherine R and Warshaw, Erin M
Dermatitis, ISSN 1710-3568, 11/2016, Volume 27, Issue 6, pp. 333 - 347
Life Sciences & Biomedicine | Dermatology | Science & Technology | Administration, Ophthalmic | Lubricant Eye Drops - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Anti-Infective Agents, Local - adverse effects | Ophthalmic Solutions - adverse effects | Glaucoma - drug therapy | Adrenergic alpha-1 Receptor Agonists - adverse effects | Histamine Antagonists - adverse effects | Facial Dermatoses - etiology | Anti-Inflammatory Agents - adverse effects | Dermatitis, Allergic Contact - etiology | Prostaglandins, Synthetic - adverse effects | Antineoplastic Agents - adverse effects | Muscarinic Agonists - adverse effects | Antiviral Agents - adverse effects | Adrenergic beta-Antagonists - adverse effects | Anti-Bacterial Agents - adverse effects | Carbonic Anhydrase Inhibitors - adverse effects | Cholinergic Antagonists - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
by Siler, Thomas M and Kerwin, Edward and Sousa, Ana R and Donald, Alison and Ali, Rehan and Church, Alison
Respiratory medicine, ISSN 0954-6111, 2015, Volume 109, Issue 9, pp. 1155 - 1163
Pulmonary/Respiratory | Bronchodilation | Long-acting muscarinic antagonist | Long-acting beta2 agonist | Inhaled corticosteroid | Long-acting beta | agonist | Cardiac & Cardiovascular Systems | Respiratory System | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Dose-Response Relationship, Drug | Vital Capacity - drug effects | Quinuclidines - therapeutic use | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Quinuclidines - adverse effects | Double-Blind Method | Muscarinic Antagonists - administration & dosage | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Quality of Life | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Consulting services | Lung diseases | Steroids | Studies | Chronic obstructive pulmonary disease | Drug dosages | Respiratory diseases | Mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial
by van Kerrebroeck, Philip and Chapple, Christopher and Drogendijk, Ted and Klaver, Monique and Sokol, Roman and Speakman, Mark and Traudtner, Klaudia and Drake, Marcus J and on behalf of the NEPTUNE Study Group and NEPTUNE Study Grp and NEPTUNE Study Group
European urology, ISSN 0302-2838, 2013, Volume 64, Issue 6, pp. 1003 - 1012
Urology | Storage symptoms | Voiding symptoms | Solifenacin | Tamsulosin OCAS | Lower urinary tract symptoms | no | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Urinary system involvement in other diseases. Miscellaneous | Tablets | Humans | Muscarinic Antagonists - adverse effects | Solifenacin Succinate | Male | Quinuclidines - administration & dosage | Adrenergic alpha-1 Receptor Antagonists - administration & dosage | Absorption | Lower Urinary Tract Symptoms - drug therapy | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Muscarinic Antagonists - pharmacokinetics | Quinuclidines - adverse effects | Double-Blind Method | Administration, Oral | Adrenergic alpha-1 Receptor Antagonists - pharmacokinetics | Tetrahydroisoquinolines - administration & dosage | Tetrahydroisoquinolines - adverse effects | Sulfonamides - pharmacokinetics | Muscarinic Antagonists - administration & dosage | Tetrahydroisoquinolines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Drug Combinations | Sulfonamides - administration & dosage | Quinuclidines - pharmacokinetics | Tamsulosin hydrochloride | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
by Füllhase, Claudius and Chapple, Christopher and Cornu, Jean-Nicolas and De Nunzio, Cosimo and Gratzke, Christian and Kaplan, Steven A and Marberger, Michael and Montorsi, Francesco and Novara, Giacomo and Oelke, Matthias and Porst, Hartmut and Roehrborn, Claus and Stief, Christian and McVary, Kevin T
European urology, ISSN 0302-2838, 2013, Volume 64, Issue 2, pp. 228 - 243
Urology | Muscarinic antagonists | Prostatic hyperplasia | 5α-reductase inhibitors | Lower urinary tract symptoms | Adrenergic α1-receptor antagonists | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Tumors of the urinary system | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Urinary system involvement in other diseases. Miscellaneous | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Lower Urinary Tract Symptoms - physiopathology | Male | Treatment Outcome | 5-alpha Reductase Inhibitors - therapeutic use | Muscarinic Antagonists - therapeutic use | Evidence-Based Medicine | Prostatic Hyperplasia - diagnosis | Lower Urinary Tract Symptoms - drug therapy | Time Factors | Adrenergic alpha-1 Receptor Antagonists - therapeutic use | 5-alpha Reductase Inhibitors - adverse effects | Lower Urinary Tract Symptoms - diagnosis | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Phosphodiesterase 5 Inhibitors - therapeutic use | Prostatic Hyperplasia - physiopathology | Drug Therapy, Combination | Prostatic Hyperplasia - drug therapy | Drugs | Medical colleges | Hospitals | Drug therapy, Combination | Drug approval | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights